Embed Size (px)
DESCRIPTION
Market Research Reports, Inc. has announced the addition of “Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape” research report to their offering. More information visit- http://mrr.cm/ZkC
Citation preview
www.MarketResearchReports.com
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-
Stage Pipeline to Transform Clinical and Commercial Landscape
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Introduction to Report
Launch Date: January 31, 2014
Number of Pages: 120
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 3,500
Price For Site License: USD 7,000
Price For Global User License: USD 10,500
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com
About the Report
Due to a large untreated patient pool and the recent approval of new treatments, the hepatitis C market will more than treble from $5.7 billion in 2012 to $18.6 billion by 2019, at an impressive Compound Annual Growth Rate (CAGR) of 18.5%.
The company’s new report* states that the hepatitis C market will receive this major boost with the 2013 approval of Sovaldi, which has the potential to transform the treatment algorithm for hepatitis C. Due to the clinical potential of the drug, Sovaldi will be very expensive, reaching a cost of $86,000 annually and setting a high price benchmark for future drugs.
www.MarketResearchReports.com
Research Findings
Analyst of this report says: “Sovaldi boasts excellent tolerability and a Sustained Virologic Response rate approaching 100%, without specificity to any genotype 1. In genotypes 2 and 3, Sovaldi is administered with ribavirin alone, alleviating the need for Pegasys or Pegintron and therefore reducing the rate of adverse events associated with these two therapies. As a result, many patients who have previously deferred treatment are expected to re-enter the market and use Sovaldi.”
Additional drugs, such as Olysio, which was also approved in 2013, and daclatasvir are anticipated to compete with Sovaldi, although they are not proven to be as effective and can only be used in genotype 1 infections.
www.MarketResearchReports.com
Research Findings Continues…
According to publisher, Sovaldi-ledipasvir and ABT-450 triple therapy will further advance the hepatitis C market and displace older drugs from 2015 onwards. This is due to the fact that these therapies can be used without peginterferon and have demonstrated 100% efficacy in genotype 1, with strong tolerability and low dosing.
“The late-stage pipeline for hepatitis C is exceptionally promising, and we expect new products to completely transform the clinical and commercial landscape during the forecast period,” Analyst concludes.
www.MarketResearchReports.com
Scope
A brief introduction to hepatitis C, including the disease’s pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms.
In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy.
A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target.
www.MarketResearchReports.com
Scope Continues…
In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.
Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Analysis of licensing and co-development deals occurring in the hepatitis C market.
www.MarketResearchReports.com
Report Coverage
1. Table of Contents2. Introduction3. Marketed Products4. Developmental Pipeline5. Market Forecast to 20196. Drivers and Barriers7. Licensing and Co-development deals8. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Custom Research: Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.
For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and purchase this publication:
http://www.marketresearchreports.com/gbi-research/hepatitis-c-therapeutics-major-developed-markets-2019-outstanding-recent-approvals-and
About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.
Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)
